NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Individuals Who Provided Content Development and/or Authorship Assistance

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

John M. Kane III, MD, Panel Vice Chair
Mary Anne Bergman, Guidelines Coordinator, NCCN
Hema Sundar, PhD, Manager, Global Clinical Content, NCCN
Lisa E. Hang, PhD, Oncology Scientist/Medical Writer, NCCN

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Margaret von Mehren, MD, Panel Chair, has disclosed receiving grant/research support from Deciphera Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Cogent Biosciences, and Theseus Pharmaceuticals, Inc.; and serving as an advisor for Boehringer Ingelheim GmbH, Deciphera Pharmaceuticals, Inc., and GlaxoSmithKline. 
Seth M. Pollack, MD, Panel Member, has disclosed serving as an advisor for Adaptimmune Therapeutics plc, Deciphera Pharmaceuticals, Inc., GlaxoSmithKline, Obsisian Therapeutics, Sensei Biotherapeutics, Inc., Springworks Therapeutics, and T-Knife GmbH; receiving grant/research support from Advenchen Laboratories, LLC, BioAtla, Inc., EMD Serono, Incyte Corporation, Obsisian Therapeutics, Rain Therapeutics, and TRACON Pharmaceuticals, Inc.; receiving consulting fees from Daiichi Sankyo, Inc., Deciphera Pharmaceuticals, Inc., Epizyme, Inc., Sensei Biotherapeutics, Inc., Springworks Therapeutics, and T-Knife GmbH; and serving in a product/speaker bureau for Deciphera Pharmaceuticals, Inc.
Richard F. Riedel, MD, Panel Member, has disclosed receiving grant/research support from Aadi Bioscience, Inc., AROG Pharmaceuticals, Inc., Ayala Pharmaceuticals, BioAtla, Inc., Cogent Biosciences, Inc., Daiichi-Sankyo Co., GlaxoSmithKline, Immune Design, Karyopharm Therapeutics, NanoCarrier Co., Ltd., Oncternal Therapeutics, Inc., Plexxikon, SpringWorks Therapeutics, TRACON Pharmaceuticals, Inc., and Trillium Therapeutics Inc.; and receiving consulting fees from Aadi Bioscience, Inc., Bayer HealthCare, Blueprint Medicines, Daiichi-Sankyo Co., Deciphera Pharmaceuticals, Inc., GlaxoSmithKline, NanoCarrier Co., Ltd., and SpringWorks Therapeutics.
Jason K. Sicklick, MD, Panel Member, has disclosed serving in a product/speakers’ bureau for Deciphera Pharmaceuticals, Inc., Foundation Medicine, Inc., La Hoffman-Roche, Merck & Co., Inc., and QED Therapeutics, Inc.; receiving grant/research support from Amgen, Inc. and Foundation Medicine, Inc.; and receiving consulting fees from Deciphera Pharmaceuticals, Inc. and Ethicon, Inc.

View all of the conflicts of interest for the NCCN Guidelines panel

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.